{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:58:53Z","timestamp":1780567133295,"version":"3.54.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jtha.2025.10.022","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:59:32Z","timestamp":1762210772000},"page":"343-353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mechanisms and treatment of venous thromboembolism in patients with brain cancer: a narrative review"],"prefix":"10.1016","volume":"24","author":[{"given":"Timothy","family":"Hoberstorfer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4663-9830","authenticated-orcid":false,"given":"Julia","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.10.022_bib1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11060-011-0738-7","article-title":"Improved survival time trends for glioblastoma using the SEER 17 population-based registries","volume":"107","author":"Koshy","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jtha.2025.10.022_bib2","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2340\/1651-226X.2024.40137","article-title":"The risk of venous thromboembolism in adult patients with diffuse glioma: a nationwide population-based study","volume":"63","author":"Hovman","year":"2024","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jtha.2025.10.022_bib3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1538-7836.2009.03690.x","article-title":"Venous thromboembolism in malignant gliomas","volume":"8","author":"Jenkins","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.10.022_bib4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Electronic address:","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtha.2025.10.022_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjh.19414","article-title":"Cancer-associated venous thrombosis in adults (second edition): a British Society for Haematology Guideline","volume":"205","author":"Alikhan","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.10.022_bib6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3171\/jns.2007.106.4.601","article-title":"Epidemiology of venous thromboembolism in 9489 patients with malignant glioma","volume":"106","author":"Semrad","year":"2007","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jtha.2025.10.022_bib7","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/cncr.35220","article-title":"Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients","volume":"130","author":"Ranjan","year":"2024","journal-title":"Cancer"},{"issue":"Suppl 4","key":"10.1016\/j.jtha.2025.10.022_bib8","doi-asserted-by":"crossref","first-page":"iv73","DOI":"10.1093\/neuonc\/nos197","article-title":"Thromboembolic disease in patients with high-grade glioma","volume":"14","author":"Perry","year":"2012","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jtha.2025.10.022_bib9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1055\/s-0044-1789592","article-title":"Venous thromboembolism in patients with glioblastoma: molecular mechanisms and clinical implications","volume":"125","author":"Kapteijn","year":"2025","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.10.022_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jocn.2015.05.053","article-title":"Venous thromboembolism in brain tumor patients","volume":"25","author":"Cote","year":"2016","journal-title":"J Clin Neurosci"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2025.10.022_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-136117","article-title":"Venous thromboembolism incidence and impact on survival in patients with brain metastases","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.10.022_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2020.04.018","article-title":"Venous thromboembolic events in patients with brain metastases: the PICOS score","volume":"134","author":"Wolpert","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtha.2025.10.022_bib13","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.10.022_bib14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s11912-021-01178-9","article-title":"Venous thrombotic events and anticoagulation in brain tumor patients","volume":"24","author":"Diaz","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jtha.2025.10.022_bib15","doi-asserted-by":"crossref","first-page":"e982","DOI":"10.1016\/j.wneu.2019.05.049","article-title":"Podoplanin expression and IDH-wildtype status predict venous thromboembolism in patients with high-grade gliomas in the early postoperative period","volume":"128","author":"Watanabe","year":"2019","journal-title":"World Neurosurg"},{"key":"10.1016\/j.jtha.2025.10.022_bib16","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2016-06-720714","article-title":"Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism","volume":"129","author":"Riedl","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.10.022_bib17","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/jth.14129","article-title":"Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism","volume":"16","author":"Mir Seyed Nazari","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.10.022_bib18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3171\/jns.1998.89.2.0200","article-title":"Correlation of intraluminal thrombosis in brain tumor vessels with postoperative thrombotic complications: a preliminary report","volume":"89","author":"Rodas","year":"1998","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jtha.2025.10.022_bib19","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/neuonc\/nou106","article-title":"Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas","volume":"16","author":"Thaler","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jtha.2025.10.022_bib20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1538-7836.2009.03680.x","article-title":"High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"8","author":"Simanek","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.10.022_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117538","article-title":"IDH mutation status and the development of venous thromboembolism in astrocytoma patients","volume":"427","author":"Mandel","year":"2021","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jtha.2025.10.022_bib22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s10014-021-00406-1","article-title":"Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma","volume":"38","author":"Osada","year":"2021","journal-title":"Brain Tumor Pathol"},{"key":"10.1016\/j.jtha.2025.10.022_bib23","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1111\/ene.15404","article-title":"Venous thromboembolic events in glioblastoma patients: an epidemiological study","volume":"29","author":"Eisele","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jtha.2025.10.022_bib24","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/jth.15739","article-title":"Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma","volume":"20","author":"Kaptein","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.10.022_bib25","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1182\/blood.2022017858","article-title":"Determining venous thromboembolism risk in patients with adult-type diffuse glioma","volume":"141","author":"Burdett","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.10.022_bib26","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.jtha.2023.04.036","article-title":"Role of circulating mitochondria in venous thrombosis in glioblastoma","volume":"21","author":"Gonzalez-Delgado","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.10.022_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.thromres.2022.11.013","article-title":"Targeted DNA sequencing to identify genetic aberrations in glioblastoma that underlie venous thromboembolism; a cohort study","volume":"221","author":"Kapteijn","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.10.022_bib28","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.3390\/curroncol30050373","article-title":"The role of EGFR amplification in deep venous thrombosis occurrence in IDH wild-type glioblastoma","volume":"30","author":"Kaye","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jtha.2025.10.022_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18149","article-title":"The plasma miRNome and venous thromboembolism in high-grade glioma: miRNA sequencing of a nested case-control cohort","volume":"28","author":"Erhart","year":"2024","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jtha.2025.10.022_bib30","article-title":"Evaluating of existing VTE risk scales in glioma patients","volume":"30","author":"Simakova","year":"2024","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.10.022_bib31","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1212\/WNL.0000000000011414","article-title":"Risk of venous thromboembolism in grade II-IV gliomas as a function of molecular subtype","volume":"96","author":"Diaz","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jtha.2025.10.022_bib32","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00401-016-1620-7","article-title":"Mutant IDH1 and thrombosis in gliomas","volume":"132","author":"Unruh","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.jtha.2025.10.022_bib33","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jtha.2025.10.022_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102664","article-title":"Risk assessment and prevention of cancer-associated venous thromboembolism in ambulatory patients with solid malignancies","volume":"9","author":"Vladic","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.10.022_bib35","first-page":"6063","article-title":"Combined analysis of clinical and laboratory markers to predict the risk of venous thromboembolism in patients with IDH1 wild-type glioblastoma","volume":"30","author":"Huang","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jtha.2025.10.022_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1413.001","article-title":"Markers for microscopic imaging of lymphangiogenesis and angiogenesis","volume":"1131","author":"Baluk","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jtha.2025.10.022_bib37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1538-7836.2011.04335.x","article-title":"Novel platelet activation receptor CLEC-2: from discovery to prospects","volume":"9","author":"Suzuki-Inoue","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.10.022_bib38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00428-005-0133-x","article-title":"Podoplanin is expressed in subsets of tumors of the central nervous system","volume":"448","author":"Shibahara","year":"2006","journal-title":"Virchows Archiv"},{"key":"10.1016\/j.jtha.2025.10.022_bib39","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/bloodadvances.2018015966","article-title":"Intratumoral platelet aggregate formation in a murine preclinical glio ma model depends on podoplanin expression on tumor cells","volume":"3","author":"Costa","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.10.022_bib40","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/jth.15544","article-title":"Podoplanin promotes tumor growth, platelet aggregation, and venous thr ombosis in murine models of ovarian cancer","volume":"20","author":"Sasano","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.10.022_bib41","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1182\/bloodadvances.2020002998","article-title":"Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles","volume":"5","author":"Tawil","year":"2021","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2025.10.022_bib42","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1016\/j.thromres.2018.01.021","article-title":"Single cell coagulomes as constituents of the oncogene-driven coagulan t phenotype in brain tumours","volume":"164","author":"Tawil","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.10.022_bib43","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1538-7836.2012.04754.x","article-title":"Microparticle-associated tissue factor activity, venous thromboembolis m and mortality in pancreatic, gastric, colorectal and brain cancer patients","volume":"10","author":"Thaler","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.10.022_bib44","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/jth.14129","article-title":"Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplan in expression in brain tumors identifies patients at high or low risk of venous thromboembolism","volume":"16","author":"Mir Seyed Nazari","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.10.022_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100758","article-title":"Wild-type IDH1 and mutant IDH1 opposingly regulate podoplanin expressi on in glioma","volume":"13","author":"Sun","year":"2020","journal-title":"Transl Oncol"},{"key":"10.1016\/j.jtha.2025.10.022_bib46","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/jth.13951","article-title":"Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients","volume":"16","author":"Mauracher","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.10.022_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009095","article-title":"Hematogenous dissemination of glioblastoma multiforme","volume":"6","author":"M\u00fcller","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtha.2025.10.022_bib48","article-title":"Circulating tumor cells and thromboembolic events in patients with glioblastoma","author":"Rolling","year":"2024","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2025.10.022_bib49","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1161\/ATVBAHA.122.318463","article-title":"Histopathological features of cancer-associated venous thromboembolism: presence of intrathrombus cancer cells and prothrombotic factors","volume":"43","author":"Gi","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2025.10.022_bib50","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.10.022_bib51","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtha.2025.10.022_bib52","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtha.2025.10.022_bib53","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtha.2025.10.022_bib54","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1182\/bloodadvances.2022008086","article-title":"ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis","volume":"6","author":"Giustozzi","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.10.022_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1638","article-title":"Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism: a meta-analysis","volume":"10","author":"Porfidia","year":"2020","journal-title":"Brain Behav"},{"key":"10.1016\/j.jtha.2025.10.022_bib56","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/jth.13387","article-title":"A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation","volume":"14","author":"Zwicker","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.10.022_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2020-324488","article-title":"Intracerebral haemorrhage in patients with brain metastases receiving therapeutic anticoagulation","author":"Wood","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jtha.2025.10.022_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2023.107243","article-title":"Risk of intracranial hemorrhage with direct oral anticoagulation versus low molecular weight heparin in the treatment of brain tumor-associated venous thromboembolism: a meta-analysis","volume":"32","author":"Yang","year":"2023","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jtha.2025.10.022_bib59","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s11239-023-02936-1","article-title":"Anticoagulant prescribing patterns in patients with primary central nervous system malignancies and secondary metastases","volume":"57","author":"Abdelmessih","year":"2024","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.10.022_bib60","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jtha.2023.10.011","article-title":"Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review","volume":"22","author":"Iyengar","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.10.022_bib61","first-page":"1417","article-title":"Multinational cohort study of intracranial hemorrhage in patients with brain metastases receiving anticoagulation","volume":"110","author":"Hamuly\u00e1k","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.10.022_bib62","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/jth.14336","article-title":"Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors","volume":"17","author":"Carney","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.10.022_bib63","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/neuonc\/noac125","article-title":"Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: A retrospective cohort study","volume":"24","author":"Reed-Guy","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jtha.2025.10.022_bib64","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.thromres.2021.10.023","article-title":"Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors","volume":"208","author":"Lee","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.10.022_bib65","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s11239-017-1536-7","article-title":"Anticoagulation for the treatment of venous thromboembolism in patients with brain metastases: a meta-analysis and systematic review","volume":"44","author":"Hunter","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.10.022_bib66","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10143-021-01539-9","article-title":"Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma","volume":"45","author":"Dubinski","year":"2022","journal-title":"Neurosurg Rev"},{"key":"10.1016\/j.jtha.2025.10.022_bib67","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1182\/blood-2019-131758","article-title":"Risk of intracerebral hemorrhage with and without anticoagulation in patients with brain metastasis: the Cleveland Clinic experience","volume":"134","author":"Kewan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.10.022_bib68","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1182\/blood-2018-99-113949","article-title":"Bleeding risk of low-molecular weight heparin vs direct oral anticoagulant in patients with intracranial tumors","volume":"132","author":"Abraham","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.10.022_bib69","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/onco.13698","article-title":"Safety of direct oral anticoagulants in central nervous system malignancies","volume":"26","author":"Swartz","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.jtha.2025.10.022_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114263","article-title":"Treating cancer-associated venous thromboembolism: a practical approach","volume":"209","author":"Van Cutsem","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtha.2025.10.022_bib71","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood.2023023450","article-title":"How I treat acute venous thromboembolism in patients with brain tumors","volume":"144","author":"Leader","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.10.022_bib72","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/rth2.12377","article-title":"Anticoagulation after intracranial hemorrhage in brain tumors: risk of recurrent hemorrhage and venous thromboembolism","volume":"4","author":"Carney","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.10.022_bib73","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11060-013-1115-5","article-title":"Perioperative thromboprophylaxis in patients with craniotomy for brain tumours: a systematic review","volume":"113","author":"Salmaggi","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jtha.2025.10.022_bib74","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s11239-023-02780-3","article-title":"Efficacy and safety of prophylaxis for venous thromboembolism in brain neoplasm patients undergoing neurosurgery: a systematic review and Bayesian network meta-analysis","volume":"55","author":"Liu","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.10.022_bib75","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.10.022_bib76","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.10.022_bib77","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1538-7836.2010.03973.x","article-title":"PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma","volume":"8","author":"Perry","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.10.022_bib78","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11239-021-02537-w","article-title":"Safety of apixaban for venous thromboembolic primary prophylaxis in patients with newly diagnosed malignant glioma","volume":"53","author":"Thomas","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.10.022_bib79","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41569-025-01144-z","article-title":"Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism","volume":"22","author":"Capodanno","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jtha.2025.10.022_bib80","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.1182\/bloodadvances.2024012713","article-title":"Selective Btk inhibition by PRN1008\/PRN473 blocks human CLEC-2, and PRN473 reduces venous thrombosis formation in mice","volume":"8","author":"Smith","year":"2024","journal-title":"Blood Adv"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625007226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625007226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:20:18Z","timestamp":1778224818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625007226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1538783625007226"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.10.022","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms and treatment of venous thromboembolism in patients with brain cancer: a narrative review","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}